Takeda aims to boost rare disease profile with Shire deal, says R & D chief

Takeda ’s $62 billion acquisition of Shire plc on Tuesday would accelerate the Japanese drugmaker’s transformation into a global pharmaceutical giant by significantly expanding its pipeline of rare disease treatments, a top executive based in Cambridge said in an interview. Andy Plump, Takeda’s chie f medical and scientific officer, said the deal was partly driven by the company’s desire to expand further into the market for so-called orphan drugs. They target small groups of patients —…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news